New study to measure antibiotic levels in breast milk
NCT ID NCT07618299
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will give 24 healthy breastfeeding women a single intravenous dose of the antibiotic fosfomycin (ZTI-01) and measure how much of the drug appears in their breast milk over 24 hours. Researchers will also estimate the potential dose a nursing infant might receive. The goal is to provide safety information for mothers who may need this antibiotic while breastfeeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fosfomycin (ZTI-01)
What this could lead to
If successful, this study will provide crucial safety data on fosfomycin use during breastfeeding, helping doctors and mothers make informed decisions.
What could go wrong
This is a small, early-phase pharmacokinetic study in healthy women, not a treatment trial. Results may not apply to all breastfeeding situations or sick mothers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY LACTATING WOMEN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••